BiomX Inc. (PHGE) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarter ended September 30, 2024. BiomX Inc. is a clinical-stage biotechnology company developing phage-based therapies for chronic bacterial infections, primarily focusing on Cystic Fibrosis (CF) and Diabetic Foot Osteomyelitis (DFO). The period was significantly impacted by the acquisition of Adaptive Phage Therapeutics LLC (APT) on March 15, 2024, and a concurrent March 2024 PIPE financing raising approximately $50 million. The company also executed a 1-for-10 reverse stock split effective August 26, 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss (Income) | $(9.6M) | $7.9M (Income) | $3.2M (Income) | $(20.7M) |
| Operating Loss | $(11.3M) | $(7.8M) | $(27.8M) | $(20.1M) |
| R&D Expenses | $7.3M | $5.6M | $18.3M | $14.0M |
| G&A Expenses | $3.2M | $2.2M | $8.8M | $6.1M |
| Cash & Equivalents | $23.5M | $14.9M (Dec 2023) | $23.5M | $14.9M (Dec 2023) |
| Debt | $0 | $5.8M (Current) | $0 | $5.8M (Current) |
| EPS (Basic) | $(0.31) | $1.30 | $0.32 | $(4.29) |
Note: The Net Income for Q3 2024 and YTD 2024 is primarily driven by a non-cash gain of $20.6M and $24.4M, respectively, from the change in fair value of Private Placement Warrants.
Material Changes vs. Prior Period
- Acquisition Impact: The consolidation of APT increased R&D and G&A expenses. R&D rose 30% QoQ and 31% YTD due to clinical trial preparations for BX004 (CF) and BX211 (DFO), plus increased rent.
- Goodwill Impairment: The company recorded a $0.8M goodwill impairment in Q3 2024 due to a decline in market capitalization below stockholders' equity.
- Debt Repayment: The company fully repaid its $15M venture debt facility with Hercules Capital in March 2024, reducing interest expense by 99% in Q3 compared to the prior year.
- Contract Liability Reversal: Other income increased significantly YTD ($2.2M vs $0.3M) due to the reversal of a $2.0M contract liability after pausing the BX005 (Atopic Dermatitis) program.
- Capital Structure: Issuance of $50M in PIPE financing (Preferred Shares and Warrants) and a 1-for-10 reverse stock split.
Outlook, Risks, and Management Commentary
- Clinical Pipeline:
- BX004 (CF): Phase 2b study initiation delayed to Q4 2024 due to manufacturing delays; results now expected in H1 2026.
- BX211 (DFO): Phase 2 trial enrollment complete; first readout expected Q1 2025.
- Paused/Discontinued: BX005 (Atopic Dermatitis) and Prosthetic Joint Infection programs are paused or discontinued to prioritize CF and DFO.
- Liquidity & Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern without additional financing. Current cash ($24.7M) is projected to fund operations into Q4 2025.
- Geopolitical Risk: Operations are based in Israel. While the ongoing war with Hamas and Hezbollah has not materially impacted operations to date, escalation or prolonged conflict poses risks to personnel, supply chains, and capital access.
- Regulatory: BX004 holds FDA Fast Track and Orphan Drug designations.
Investor Verification Checklist
- Warrant Liability Volatility: Verify the impact of the Private Placement Warrants on future earnings, as fair value changes create significant non-cash income/loss volatility.
- Cash Burn Rate: Confirm the runway calculation given the "substantial doubt" disclosure and the need for future capital raises.
- Manufacturing Delays: Assess the specific causes and mitigation plans for the BX004 manufacturing delays pushing results to 2026.
- Goodwill Status: Monitor if the goodwill impairment is a one-time event or indicative of further valuation pressure.
- Israel Operations: Review updates on employee reserve duty and potential supply chain disruptions related to the regional conflict.